Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684095 | 1.00 | KCNH2 (0.78) | KCNH2CYP2C9MAP2K1MAP2K2BRAF | |
| SCHEMBL1615228 | 0.90 | KCNH2 (0.78) | KCNH2CYP2C9MAP2K1MAP2K2BRAF | |
| SCHEMBL29683598 | 0.90 | KCNH2 (0.78) | KCNH2CYP2C9MAP2K1MAP2K2BRAF | |
| SCHEMBL18788196 | 0.90 | KCNH2 (0.64) | KCNH2CYP2C9MAP2K1MAP2K2BRAF | |
| SCHEMBL1616128 | 0.90 | KCNH2 (0.63) | KCNH2CYP2C9MAP2K1MAP2K2 | |
| SCHEMBL29683678 | 0.90 | KCNH2 (0.63) | KCNH2CYP2C9MAP2K1MAP2K2 | |
| SCHEMBL12646898 | 0.88 | KCNH2 (0.69) | KCNH2CYP2C9MAP2K1MAP2K2BRAF | |
| SCHEMBL1616174 | 0.88 | CYP2C9 (0.76) | KCNH2CYP2C9MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL29683672 | 0.88 | KCNH2 (1.00) | KCNH2CYP2C9MAP2K1 | |
| SCHEMBL12589902 | 0.88 | KCNH2 (0.70) | KCNH2CYP2C9MAP2K1MAP2K2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | claimed |
| US-10946093-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10646567-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3563870-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| EP-3169361-B1 | COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| US-20180021431-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9724413-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170112925-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2016011160-A1 | COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | GENENTECH, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120309765-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8288408-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110158990-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2009085983-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946093-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | CD274, PDCD1, PDCD1LG2 | KCNH2 4598/4885CYP2C9 4843/4885MAP2K1 13/4885 |
| US-10646567-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | CD274, PDCD1, PDCD1LG2 | KCNH2 4598/4885CYP2C9 4843/4885MAP2K1 13/4885 |
| US-20180021431-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | KCNH2 4598/4885CYP2C9 4843/4885MAP2K1 13/4885 |
| US-20120309765-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | KCNH2 2040/4885CYP2C9 3917/4885MAP2K1 999/4885 |
| US-20110158990-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | KCNH2 2040/4885CYP2C9 3917/4885MAP2K1 999/4885 |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, MAP3K5, MAPKAPK5 | KCNH2 1382/4885CYP2C9 2665/4885MAP2K1 64/4885 |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | KCNH2 2040/4885CYP2C9 3917/4885MAP2K1 999/4885 |
| US-20170112925-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | CD274, PDCD1, PDCD1LG2 | KCNH2 4598/4885CYP2C9 4843/4885MAP2K1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.